WILLOW BIOSCIENCES INC - CANSF STOCK NEWS

Willow Biosciences Inc. (OTCQB: CANSF) has announced a commercial agreement with Sandhill One, LLC, following successful development of their BioOxi™ bio-oxidation platform for ursodeoxycholic acid (UDCA). This bioactive compound is essential in treating cholestatic liver disease and gallstone conditions. The innovative collaboration aims to provide a more sustainable, cost-effective production method for UDCA, eliminating reliance on animal-sourced materials. Willow anticipates receiving a significant percentage of Sandhill’s end-market revenues, enhancing potential royalty income. The agreement underscores Willow's commitment to expanding company growth and achieving targeted milestones for 2023.

Willow Biosciences Inc. (OTCQB: CANSF) has launched its new BioOxi™ platform, enhancing its strain engineering and precision fermentation capabilities. This technology streamlines the production of oxygenated and hydroxylated functional ingredients by eliminating several chemical steps, which significantly lowers production costs and resources. The platform aims to expand revenue opportunities by providing faster product innovation for commercial partners. Willow's recent collaborations show the potential for BioOxi to support new business developments and generate additional licensing or royalty revenues. The company believes this strategic move will broaden its market and accelerate revenue generation in the rapidly evolving biotech sector.

Willow Biosciences Inc. (CANSF) announced key management promotions and changes to its Board of Directors on March 28, 2023. Dr. Chris Savile has been appointed as President and CEO, succeeding Dr. Peter Seufer-Wasserthal, who will remain a director. Dr. Savile has been instrumental in developing Willow's biotechnological capabilities since its inception in 2019. Additionally, Dr. Trish Choudhary has been promoted to Sr. VP Research and Development. The Board will welcome Mr. Raffi Asadorian as an independent director post the AGM on May 12, 2023. These changes come as part of Willow's transition towards becoming a fully-integrated precision fermentation company.

On March 22, 2023, Willow Biosciences (CANSF) and Suanfarma announced the successful completion of pilot-scale development and manufacturing for Cannabigerol (CBG) at Suanfarma's CIPAN manufacturing site. The project aims to fulfill the production batches required for qualification and registration by the end of 2023.

Willow's CBG is positioned for health, wellness, and consumer care applications, demonstrating safety and efficacy as an antioxidant and anti-inflammatory agent. The partnership aims to offer an end-to-end synthetic biology solution and enhance their product portfolio for pharmaceuticals and natural ingredients.

Willow Biosciences Inc. has appointed Dr. Jim Lalonde as an independent member of its Board of Directors, effective February 21, 2023. Dr. Lalonde is recognized for his contributions to enzyme engineering and biocatalysis, which have significantly advanced chemical production and drug development. With a history of strengthening R&D teams and driving business growth, his expertise is expected to support Willow's focus on expanding its R&D capabilities and diversifying its portfolio. Dr. Lalonde aims to leverage Willow's precision fermentation technology to foster innovation in health, wellness, food, and personal care markets.

Willow Biosciences Inc. (OTCQB: CANSF) has announced a follow-on engagement with Sandhill One, LLC to optimize a proprietary enzyme for the production of ursodeoxycholic acid (UDCA), an active pharmaceutical ingredient. This collaboration marks progress towards the company’s growth goals for 2023, aiming for increased revenue. The partnership with a major healthcare company focuses on a process that eliminates reliance on animal-sourced materials, promising cost-effective production. Willow anticipates several hundred thousand USD in research fees and future milestone payments as it moves towards commercialization of the enzyme by the end of the year.

Willow Biosciences Inc. (CANSF) has reviewed its key milestones achieved in 2022 and its business outlook for 2023. Major accomplishments include optimizing a new cannabigerol (CBG) process for commercial production, collaborations with Kalsec Inc., and the development of Astaxanthin, with a market potential exceeding $1 billion by 2027. For 2023, the company aims for substantial revenue growth, new partnerships, and efficient production. Willow has terminated a Joint Development Agreement for CBD to gain full control over its future in this market, emphasizing strategic optimization and a sustainable approach.